( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .



    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR JULY 2024 Issue has been Published, Kindly check it on


    JULY 2024 Issue has been successfully launched on JULY 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here




Dr. Natiq D. Shalaan*


Background: Emergence from general anesthesia can be associated with coughing, agitation, hypertension, and tachycardia, which may cause bleeding from the surgical site, and an increase in intracranial and intraocular pressure. In addition to respiratory complications, hemodynamic complications such as hypertension, increasing intraocular and intracranial pressure, tachycardia, and dysrhythmia can occur with extubation that can be hazardous in high-risk patients. Remifentanil is an opioid with instant effect and rapid elimination that is not influenced by age or the functions of the liver and kidneys, and does not result in delayed recovery or respiratory depression after a continuous infusion and recently it has been recommended as a promising agent in attenuating hemodynamic and respiratory complications of anesthesia. Patients and Methods: This prospective clinical trial, case control study, Including one hundred twenty adult patients undergoing lower abdomen, orthopedics or plastic surgery. All patients received a standard general anesthesia. At the end of surgery, Group A received a bolus dose of remifentanil 0.5 microgram/kilogram (N = forty), Group B received 1microgram/kilogram remifentanil (N= forty) and Group C received placebo (normal saline) (N = forty), when extubation criteria were achieved non- invasive arterial pressure, heart rate and oxygen saturation were measured 1minute before extubation, remifentanil was given over 30 seconds, and tracheal extubation was performed. Non-invasive arterial pressure, heart rate and oxygen saturation also measured 1minute intervals after extubation to fifth minute. Results: One hundred twenty patients enrolled the study. 73 of them were male and 47 female, age of 27.47 ± 5.96 years, weight of 75.57 ± 7.96 kg. Patients who developed apnea after endotracheal extubation are (18.33%), 5% of group A and 50% of group B while none of the group C, and P – value was very significant (0.0001). Were no statistically significant associations between different study groups and both of age and weight of the patients, P – values were not significant and more than 0.05. Except for 1 minute before extubation there was statistically significant association between the different study groups and SBP,DBP,MAP and HR readings before and after extubation follow ups. In all conditions patients from group C had the highest SBP, DBP, MAP and HR readings followed by group A then group B, P – value was significant and less than 0.05. There was no statistically significant association between study groups and SaO2, P – values were higher than 0.05. Conclusions: Patients receiving remifentanil are hemodynamically stable during and after endotracheal extubation in compare with patients receiving normal saline. Patients receiving remifentanil 0.5mcg/kg, hemodynamic measures more close to normal values and less incidence of apnea than patients whose receiving remifentanil 1mcg/kg. No difference in oxygen saturation and no significant associations between different study groups and both of age and weight of the patients among three groups.

[Full Text Article] [Download Certificate]